Zacks Investment Management
CRVS icon

Zacks Investment Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Zacks Investment Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,000
Closed -$48K – 626
2021
Q3 		$48K Buy
+10,000
New +$29.6K ﹤0.01% 589

Other funds holding CRVS

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Zacks Investment Management's CRVS Position: Q4 2021 in Review

Zacks Investment Management sold out of Corvus Pharmaceuticals (CRVS) in Q4 2021, closing a stake of 10,000 shares — an estimated $48K sold.

Zacks Investment Management first reported a position in CRVS in Q3 2021 and held it in 1 quarter. The position peaked at $48K in Q3 2021. 62 funds tracked by Wall St. Rank hold CRVS as of Q4 2021.

  • Zacks Investment Management reported no remaining Corvus Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Zacks Investment Management sold 10,000 Corvus Pharmaceuticals shares in Q4 2021, an estimated $48K.
  • Zacks Investment Management first reported a position in Corvus Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Zacks Investment Management's Corvus Pharmaceuticals position peaked at $48K in Q3 2021.
  • 62 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2021.

Based on Zacks Investment Management's 13F filing for Q4 2021, filed 15 Feb 2022.